- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02022514
Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.
Phase III Clinical Trial, Multicentric, Open, Randomized and Controlled to Assess the Effectiveness of Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.
Clinical trial phase III, prospective, controlled, randomized, open.
We hypothesize work that patients with chronic coronary occlusion and poor myocardial viability who failed to recover ventricular function after subjecting coronary revascularization with new techniques of recanalization, could achieve an improvement of ventricular function if given further regenerative treatment with mononuclear cells from autologous bone marrow.
To test this hypothesis we designed a prospective, randomized clinical trial in patients with recanalized chronic occlusions and ventricular dysfunction.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a randomized, open label prospective clinical trial in which all patients diagnosed with chronic coronary occlusion in the Cardiology Department of Hospital Reina Sofía in Cordoba and Hospital Puerta del Mar in Cadiz, who meet inclusion criteria and none of the exclusion shall include and express their accordance with trial participation by signing the informed consent.
66 patients who did not improve ventricular function measured by Magnetic resonance at least 3 months after revascularization of chronic coronary occlusion will be included . The 66 patients will be randomized in one to one ratio to an intervention group that received bone marrow mononuclear cells by intracoronary autologous (0.5 to 1 x 10 9 total cells) and a control group who receive only conventional medical treatment. The two groups of patients will be followed, in the clinical trial, for 6 months. Once the test is complete, they will follow according to standard clinical practice of Cardiology hospital for at least 24 months.
Patients will be assessed by clinical and Magnetic resonance methods. All patients will be medically treated similarly with ACE inhibitors or angiotensine 1 receptor (AT1) receptor antagonists of angiotensin II, beta-blockers and diuretics.
The main objective os the study is to determine the efficacy of intracoronary infusion of mononuclear cells from autologous bone marrow in patients with chronic coronary occlusion previously revascularized with stents in terms of improved ventricular function determined by magnetic resonance.
Secondary objectives of the study are:
- To confirm, in view of the obtained results, the suitability of the proved protocol for the treatment of chronic coronary occlusion.
- To study changes in functional class (I-IV NYHA) of these patients compared with the control group.
- To evaluate the safety of treatment, the analysis of possible cardiac events during the 6-month follow-up in the clinical trial and 24 months of additional clinical follow-up (death, myocardial infarction, repeat revascularization) compared with the control group.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cadiz, Spain, 11009
- Dr. Alejandro Gutierrez
-
Sevilla, Spain, 14004
- Hospital U. Reina Sofía
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who give their informed consent to participate in this clinical trial.
- Patients of both sexes with atherosclerotic coronary artery disease and chronic occlusions that recanalization has been achieved successfully implanted medicated stents, and in which nevertheless persists ventricular dysfunction evaluated by magnetic resonance.
- Aged between 18 and 80 years.
- Magnetic resonance performed at least 3 months of recanalization, the ejection fraction patient should remain below or iqual to 45%.
- Normal renal function or mild renal insufficiency with serum creatinine exceeding 2.5 mg / dl.
- Normal hepatic transaminases values function < 2,5 times the upper limit of the normal range.
Hemogram and coagulation studies were within normal values, defined by:
- Leucocytes ≥ 3000
- Neutrophils ≥ 1500
- Platelets ≥ 100000
- Hemoglobin > 10g/dl
- Blood pregnancy test with negative results in the case of patients of childbearing age.
- Acceptance by patients (both men and women) of childbearing age to use safe contraceptive methods throughout the study, including the six month follow-up.
- Willingness and ability to implement the program of visits, treatment plan, laboratory tests, and all study procedures.
Exclusion Criteria:
- Patients with chronic occlusions that recanalization were not achieved successfully.
- Patients with ejection fractions upper to 45% after 3 months of recanalization.
- Positive serology for HIV, HCV or HBV.
- Coexistence of other serious systemic diseases or contraindication for double antiaggregation (clopidogrel and aspirin).
- Coexistence of any type of hematological disease.
- Pregnant, breast-feeding, or women of childbearing age who are not using effective contraception. A woman of childbearing age is considered to be all women from the age of 18 and up to one year after the last menstruation in the case of menopausal women.
- Patients who are currently participating or have completed their participation in a clinical trial within a period of less than 3 months or who have participated in a clinical trial of Advanced Therapies (cell therapy, gene therapy or tissue engineering) at any time before and has been assigned to an experimental group.
- Patients with malignant or pre-malignant tumors.
- Patients in whom an MRI cannot be performed because they carry devices incompatible with the MRI (prostheses, defibrillators, pacemakers, etc).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mononuclear cells from autologous bone marrow
Mononuclear bone marrow cells autologous intracoronary
|
Mononuclear bone marrow cells autologous intracoronary
|
Active Comparator: Conventional medical treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint will be the change in ejection fraction measured by magnetic resonance between inclusion and at 6 months follow-up
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes of NYHA functional grade comparative manner between the groups.
Time Frame: 6 months
|
6 months
|
Possible cardiac events during follow-up (death, myocardial infarction, repeat revascularization).
Time Frame: 6 months
|
6 months
|
Need for hospital admission or presence of major arrhythmia
Time Frame: 6 months
|
6 months
|
Changes in global and segmental left ventricular function
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Mauel Pan Álvarez-Ossorio, MD, PhD, Hospital Universitario Reina Sofia
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMMo/OCC/2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Atherosclerosis and Other Heart Disease
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Herlev HospitalEnrolling by invitationCardiovascular Diseases | Coronary Atherosclerosis and Other Heart DiseaseDenmark
-
Johns Hopkins UniversityNorthwestern UniversityCompletedCoronary Artery Disease | Coronary Arteriosclerosis | Coronary Atherosclerosis | Atherosclerosis, Coronary | Arteriosclerosis, CoronaryUnited States
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
Radboud University Medical CenterUMC Utrecht; Catharina Ziekenhuis Eindhoven; St. Antonius Hospital; Noordwest Ziekenhuisgroep and other collaboratorsEnrolling by invitationCoronary Vasospasm | Coronary Microvascular Dysfunction | Non-Obstructive Coronary AtherosclerosisNetherlands
-
University Hospital, IoanninaUnknownCoronary Atherosclerosis | AdipokinesGreece
-
Meshalkin Research Institute of Pathology of CirculationCompletedCoronary Artery Disease | Ischemic Heart Disease | Coronary Atherosclerosis | Coronary Artery StenosisRussian Federation
-
Segeberger Kliniken GmbHCompletedCoronary Atherosclerosis Due to Severely Calcified Coronary LesionGermany
-
Johns Hopkins UniversityRecruitingCoronary Artery Disease | Atherosclerosis | Coronary Atherosclerosis of Native Coronary ArteryUnited States
-
Odense University HospitalCompletedIschemic Heart Disease | Percutaneous Coronary Intervention | Coronary AtherosclerosisDenmark
-
Eva Rumiz GonzálezHospital Clinic of Barcelona; Hospital General Universitario Elche; Hospital... and other collaboratorsRecruitingIschemia | Coronary Disease | Non-Obstructive Coronary AtherosclerosisSpain
Clinical Trials on Mononuclear cells from autologous bone marrow
-
TotipotentSC Scientific Product Pvt. Ltd.Thermogenesis Corp.CompletedCritical Limb IschemiaIndia
-
Andalusian Network for Design and Translation of...Carlos III Health InstituteCompletedDiabetic Foot | Peripheral Vascular DiseasesSpain
-
Vinmec Healthcare SystemCompleted
-
The University of Texas Health Science Center,...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedIschemic StrokeUnited States
-
Hebei Medical UniversityUnknownDiabetes | Lower Limb IschemiaChina
-
Chinese PLA General HospitalUnknownLeft Ventricular Dysfunction | Chronic Myocardial Ischemia | Old Myocardial InfarctionChina
-
National Cerebral and Cardiovascular CenterInstitute of Biomedical Research and Innovation, Kobe, Hyogo, JapanCompletedStroke | Cerebral EmbolismJapan
-
The University of Texas Health Science Center,...CompletedTraumatic Brain InjuryUnited States